Replies to post #243332 on Avid Bioservices Inc (CDMO)

[biopharm]

CALICO, I forgot to say that time is running out. Mr. Art Levinson... please tell the bosses that Robert Garnick knows exactly what he is doing and to open up the Google search engine safe of profits and withdraw Billions to pour upon Peregrine. I'm sure a percentage deal could be worked out and I can't believe that my #1 choice is not looking to be in first place after the collaborations seen in the prior post with Allergan and seeing Pfizer all hot and bothered, and ready to mingle with Allergan.

Luhrs and Parseghian...interesting duo and just so happened to notice that Parseghian has recent work with 11 authors and one of them at Peregrine ... hmmmmmm...

Pfizer and Allergan and ??? coming soon after Peregrine ? ... but then we have Zhou from Nant Bioscience owned by Patrick Soon-Shiong and hell... maybe they need a few big backers in order to afford to get a stake in Peregrine Pharmaceuticals
..
..
..

[north40000]

biopharm, you said:

"Allergan is known for its specialty in eye care and Peregrines pipeline could help them out, in addition to expanding into other oncology areas where they are not well known at all.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=91787866&txt2find=allergan "

I know PPHM pipeline could be of interest to both PFE and AGN. But PFE eye care current interest is in U.K. with a film based cell treatment for dryAMD, itself a huge market of many Billions$$$ world-wide.

I talked with my opthalmologist today, who expressed interest in the potential PFE/AGN merger. He and I agreed that, with both AGN and PFE being interested in eye care, either or both might place a competing bid for OCAT re Astellas TO bid of $8.50/share. OCAT is initiating Phase 2 treatments of dryAMD with a suspension of its cells. One SH class action suit, said to be filed by a SH affiliated with BlackRock, has already been filed in Delaware, with allegations inter alia that Astellas' bid grossly undervalues OCAT's shares.

[biopharm]

Desmond Pink ... just 1 of the 11 in collaboration, including with Peregrine Pharmaceuticals Van Nguyen. Bet this collaboration had some ties to that RBOC Royal Bank of Canada ...

dia76ca, we need that list again : )

-------------------------------------------------------

Desmond Pink:

Biography:

Dr Pink is a Research Associate with Dr John Lewis (University of Alberta). His main work areas include (1) preclinical development of novel biomarkers for prostate cancer screening and diagnosis, (2) small molecule library screening for various cancer therapeutic applications and (3) preclinical development of a liposomal / nanoparticle drug delivery platform.

His main focus is the development of prostate cancer microparticle biomarkers. Together with his co-workers, Dr Pink has identified new markers which are used in a "liquid biopsy" to detect and enumerate microparticles and which are not only prostate cancer specific, but also indicative of disease status (e.g. normal, benign or metastatic).

The team is currently working on both retrospective and prospective sample analyses to further validate this assay but also and in collaboration with others, to identify and develop new prostate cancer specific biomarkers using proteomics, metabolomics and genetics.

While Dr Pink’s main area of interest is the development of a liquid biopsy for prostate cancer microparticle biomarkers, his broad interest lies with assay and platform development for preclinical applications. The Lewis lab utilizes many standard assay protocols, but it is best known for the development and use of the ex ovo chicken embryo model, also known as the chorioallantoic membrane or CAM model. This model system is used for investigating angiogenesis, metastasis, tumour biology, tumour vascular permeability, and nanoparticle, imaging agent and drug delivery. The system has permitted the team to investigate and develop many imaging agents, biomarkers, antibodies, small molecule drugs with real time, and quantitative analyses under in vivo conditions. Much of Dr Pink’s previous work was spent developing a real time, intravital tumour vascular permeability assay in the CAM model system.

http://www.aus-canprostatealliance.org/Members/desmond.pink-40ualberta.ca

------------------

Desmond Pink, PhD
Research Associate, Dr. John Lewis Laboratory, Department of Oncology, University of Alberta

http://apcari.ca/meet-the-team/john-d-lewis-research-group/desmond-pink/

-----------------

Desmond Pink:

Top Co-authors
View all

John D Lewis (10)
University of Alberta

Andries Zijlstra (5)
Vanderbilt University

Roxane Paulin (2)
Laval University

Missag H Parseghian (2)
Rubicon Biotechnology

http://www.researchgate.net/profile/Desmond_Pink

----------------------------------------

[biopharm]

Pfizer website detailing Histones inducing PS exposure...

2014

Histones induce phosphatidylserine exposure and a
procoagulant phenotype in human red blood cells

http://www.pfizerpro.com.co/sites/g/files/g10017511/f/publicaciones/102014%20V12I10-%20Histones%20induce%20phosphatidylserine%20exposure%20and%20a%20proagulant%20phenotype%20in%20human%20red%20blood%20cells.pdf

[biopharm]

Luhrs and Parseghian...interesting duo and just so happened to notice that Parseghian has recent work with 11 authors and one of them at Peregrine

11 authors, including:

1)Desmond Pink
Research Scientist at Innovascreen Inc

2)Keith Luhrs
Research Investigator at Allergan

3)LONGEN ZHOU
Head, Preclinical Development at NantBioScience

4)Wendy Schulte

5)Christian Frosch
Owner & Founder at BioBroker IT&Life Sciences

6)Udo Haberl

7)Van Nguyen
Research Scientist at Peregrine Pharmaceuticals

8)Aparna Illa Roy
City of Hope

9)John D. Lewis

10)Andries Zijlstra
Assistant Professor at Vanderbilt University Medical Center in the field of cancer metastasis and translational biology

11)Missag Hagop Parseghian
Founding Partner / Chief Scientific Officer..

Reviewing some PS Targeting researchers and I also found this site in regards to this collaboration above....but below it shows an added Jennifer Chase working with Pergrine Aparna I Roy.

Anyhow, some of the names like Jian Gong or Van Nguyen must have really seen the benefits of PS Targeting and Longhen Zhou at BeiGene (with Dr Jedd Wolchok and Dr Rolf Brekken) with BioDuro
https://bioduro.com/article/dow-agrosciences-bioduro-to-collaborate-on-crop-protection-discovery-research/

High efficacy vasopermeability drug candidates identified by screening in an ex ovo chorioallantoic membrane model.

Authors:

Desmond Pink
University of Alberta
Edmonton | Canada

Keith A Luhrs
Allergan Inc.

Longen Zhou
University of California
United States

Wendy Schulte
Innovascreen Inc.

Jennifer Chase
Laboratory of Intracellular Parasites

Christian Frosch
BioBroker

Udo Haberl

Van Nguyen
College of Pharmacy
Tucson | United States

Aparna I Roy
Peregrine Pharmaceuticals Inc.

John D Lewis,

Andries Zijlstra,

Missag H Parseghian

Sci Rep 2015 Oct 29;5:15756. Epub 2015 Oct 29.

Peregrine Pharmaceuticals Inc., 14282 Franklin Avenue Tustin, CA, 92780, USA.

October 2015 2 Reads

https://www.pubfacts.com/detail/26510887/High-efficacy-vasopermeability-drug-candidates-identified-by-screening-in-an-ex-ovo-chorioallantoic-

______(2016)

Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers

Michael J. Gray,
Jian Gong,
Michaela M. S. Hatch,
Van Nguyen,
Christopher C. W. Hughes,
Jeff T. Hutchins and
Bruce D. Freimark

https://breast-cancer-research.biomedcentral.com/articles/10.1186/s13058-016-0708-2


____ (2015)

Abstract Number: 252

Presentation Title: Antibody-mediated phosphatidylserine blockade significantly enhances the efficacy of immune checkpoint blockades in K1735 and B16 mouse melanoma models
Presentation Time: Sunday, April 19, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time
Location: Section 12
Poster Board Number: 10

Author Block:

Bruce Freimark1,
Jian Gong1,
Dan Ye2,
Rolf Brekken2,
Shen Yin1,
Jeff Hutchins1,
Van Nguyen1,
Chris Hughes3,
Xianming Huang2.

1Peregrine Pharmaceuticals, Inc, Tustin, CA;
2UT Southwestern Medical Center, Dallas, TX; 3University of California, Irvine, Irvine, CA

Abstract Number: 4289

Presentation Title: Targeting of phosphatidylserine by monoclonal antibodies enhances the activity of immune checkpoint inhibitors in breast tumors
Presentation Time: Tuesday, April 21, 2015, 1:00 PM - 5:00 PM Eastern Daylight Time
Location: Section 24
Poster Board Number: 19

Author Block:

Jian Gong,
Shen Yin,
Van Nguyen,
Jeff Hutchins,
Bruce D. Freimark.

Peregrine Pharmaceuticals, Inc., Tustin, CA

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=906405


___________ (2014)


Targeting of phosphatidylserine by monoclonal antibodies enhances activity of immune checkpoint inhibitors in breast tumors

Jian Gong,
Van Nguyen,
Shen Yin,
Rich Archer,
Emely Nguyen,
Jeff Hutchins and
Bruce Freimark

Journal for ImmunoTherapy of Cancer20142(Suppl 3):P206
https://doi.org/10.1186/2051-1426-2-S3-P206©; Gong et al.; licensee BioMed Central Ltd. 2014
Published: 6 November 2014

https://jitc.biomedcentral.com/articles/10.1186/2051-1426-2-S3-P206


__________(2013)

Abstract Number 2850
Presentation Title: Predicting anti-tumor responses to phosphatidylserine targeting antibodies using tumor imaging
Presentation Time: Tuesday, Apr 09, 2013, 8:00 AM - 12:00 PM EDT
Location: Hall A-C, Poster Section 21
Poster Board Number: 22
Author Block: Jian Gong (1), Richard Archer(1), Van Nguyen(1), Christopher C.W. Hughes(2), Jeff Hutchins(1), Bruce Freimark(1). 1. Peregrine Pharmaceuticals, Inc., Tustin, CA; 2. University of California, Irvine, Irvine, CA

http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=409309


_________ (2012)


Abstract Number: 2510
Presentation Title: Increased Fc-FcR interaction of human phosphatidylserine targeting antibody enhances pro-inflammatory and ADCC anti-tumor mechanisms
Presentation Time: Monday, Apr 02, 2012, 1:00 PM - 5:00 PM
Location: McCormick Place West (Hall F), Poster Section 19
Poster Board Number: 5

Author Block:

Jeanette R. Doerr1,
Gary Larson1,
Rich Archer1,
Jian Gong1,
Van Nguyen1,
Aditi Iyengar1,
Amy E. Johnson1,
Mary Wakabayashi1,
Matthew Peacock2,
Christopher Hughes2,
Connie Chang1,
Bruce Freimark1.

1. Peregrine Pharmaceuticals, Tustin, CA;
2. Univ. of California at Irvine, Irvine, CA

Abstract Number: 2452
Presentation Title: Tumor detection and measurement of responses to chemotherapy using human phosphatidylserine targeting antibody fragments
Presentation Time: Monday, Apr 02, 2012, 1:00 PM - 5:00 PM
Location: McCormick Place West (Hall F), Poster Section 16
Poster Board Number: 25

Author Block:

Jian Gong1,
Rich Archer1,
Matthew Peacock2,
Christopher Hughes2,
Connie Chang1,
Bruce Freimark1.

1. Peregrine Pharmaceuticals, Inc., Tustin, CA;
2. Univ. of California at Irvine, Irvine, CA

Abstract Number: 2454
Presentation Title: In vivo binding of chTNT-1/B antibodies (Cotara) to DNA/histone complexes in tumors using near-infrared optical imaging
Presentation Time: Monday, Apr 02, 2012, 1:00 PM - 5:00 PM
Location: McCormick Place West (Hall F), Poster Section 16
Poster Board Number: 27

Author Block:

Jian Gong1,
Roy Sevilla1,
Vince Nguyen1,
Seth Fisher1,
Jessica Alldredge1,
Jessie Kinjo1,
Rich Archer1,
Matthew Peacock2,
Christopher Hughes2,
Connie Chang1,
Bruce Freimark1.

1. Peregrine Pharmaceuticals, Inc., Tustin, CA;
2. Univ. of California at Irvine, Irvine, CA

http://m.marketwired.com/press-release/peregrine-announces-seven-abstracts-accepted-presentation-aacr-2012-annual-meeting-nasdaq-pphm-1626611.htm


______________